Renovaro Biosciences Inc. (RENB) Comparison with companies in other sectors?

Renovaro Biosciences Inc. has a share price of 230.93M. You can analyze Renovaro Biosciences Inc. (RENB) competitors across different market sectors through stock heatmaps.

What are RENB's NET and operating margins?

Renovaro Biosciences Inc. (RENB) operating margin is around -436.21, and net profit margin is approximately -369.28 as of the latest reports.

In what way does RENB's earnings per share (EPS) trend reflect its financial momentum?

Renovaro Biosciences Inc. (RENB) EPS is -0.25 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Renovaro Biosciences Inc. is -1.03, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Renovaro Biosciences Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Renovaro Biosciences Inc. like P/E which is -0.61, P/B which is 0.46, and PEG which is -0.02. Compare them with sector averages to evaluate if the stock is priced fairly.

Renovaro Biosciences Inc.

RENB•NASDAQ

Healthcare

Biotechnology

$0.26

$0.003(1.17%)

Renovaro Biosciences Inc. (RENB) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.25

P/E Ratio

-1.03

ROE

-0.67%

Net Margin

-369.28%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$59.70M

Shares OutstandingTotal number of shares issued

$230.93M

Book Value/ShareNet worth per share

$0.54

Revenue/ShareAnnual revenue per share

$0.001

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.25

Net MarginNet income as percentage of revenue

-36927.74%

Operating MarginOperating income as percentage of revenue

-43620.77%

ROEReturn on shareholders' equity

-66.92%

ROAReturn on total assets

-56.92%

ROCEReturn on capital employed

-89.05%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$72715.87

Cash/ShareCash and equivalents per share

$0.01

FCF YieldFree cash flow as percentage of market cap

19905209.81%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RENBFinancial Ratios Analysis details for RENB are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RENBSector Benchmarking details for RENB are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Renovaro Biosciences Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Renovaro Biosciences Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Renovaro Biosciences Inc.'s unique business strengths and challenges.

Key Financial Metrics for Renovaro Biosciences Inc.

For Renovaro Biosciences Inc., essential financial indicators include EPS -0.25, PE -1.03, and ROE -0.67. These key ratios reveal insights into Renovaro Biosciences Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Renovaro Biosciences Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Renovaro Biosciences Inc.

Metrics like Net Margin -36927.74% and ROA -56.92% shed light on how well Renovaro Biosciences Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Renovaro Biosciences Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Renovaro Biosciences Inc.

Using ratios such as P/B Ratio 0.46 and PEG Ratio -0.02, investors can assess whether Renovaro Biosciences Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Renovaro Biosciences Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Renovaro Biosciences Inc.

Financial health indicators, such as Debt/Equity Ratio 0.08 and Cash Flow $72715.87, provide a snapshot of Renovaro Biosciences Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Renovaro Biosciences Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Renovaro Biosciences Inc.

Investing in Renovaro Biosciences Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Renovaro Biosciences Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;